Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
18 07 2019
Historique:
received: 06 12 2018
accepted: 18 06 2019
entrez: 20 7 2019
pubmed: 20 7 2019
medline: 18 12 2019
Statut: epublish

Résumé

Knowledge of key drivers and therapeutic targets in mucosal melanoma is limited due to the paucity of comprehensive mutation data on this rare tumor type. To better understand the genomic landscape of mucosal melanoma, here we describe whole genome sequencing analysis of 67 tumors and validation of driver gene mutations by exome sequencing of 45 tumors. Tumors have a low point mutation burden and high numbers of structural variants, including recurrent structural rearrangements targeting TERT, CDK4 and MDM2. Significantly mutated genes are NRAS, BRAF, NF1, KIT, SF3B1, TP53, SPRED1, ATRX, HLA-A and CHD8. SF3B1 mutations occur more commonly in female genital and anorectal melanomas and CTNNB1 mutations implicate a role for WNT signaling defects in the genesis of some mucosal melanomas. TERT aberrations and ATRX mutations are associated with alterations in telomere length. Mutation profiles of the majority of mucosal melanomas suggest potential susceptibility to CDK4/6 and/or MEK inhibitors.

Identifiants

pubmed: 31320640
doi: 10.1038/s41467-019-11107-x
pii: 10.1038/s41467-019-11107-x
pmc: PMC6639323
doi:

Substances chimiques

Biomarkers, Tumor 0
MDM2 protein, human EC 2.3.2.27
Proto-Oncogene Proteins c-mdm2 EC 2.3.2.27
CDK4 protein, human EC 2.7.11.22
Cyclin-Dependent Kinase 4 EC 2.7.11.22
TERT protein, human EC 2.7.7.49
Telomerase EC 2.7.7.49

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3163

Subventions

Organisme : Cancer Research UK
ID : 14356
Pays : United Kingdom

Références

Nature. 2010 Oct 28;467(7319):1061-73
pubmed: 20981092
Curr Protoc Bioinformatics. 2016 Dec 8;56:15.9.1-15.9.17
pubmed: 27930809
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Nat Commun. 2014 Oct 29;5:5224
pubmed: 25351503
Nat Genet. 2017 Mar;49(3):349-357
pubmed: 28135248
Clin Cancer Res. 2013 Dec 15;19(24):6696-702
pubmed: 24345920
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Melanoma Res. 2017 Jun;27(3):189-199
pubmed: 28296713
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Nature. 2017 May 11;545(7653):175-180
pubmed: 28467829
Am J Pathol. 2009 Apr;174(4):1524-33
pubmed: 19342374
Clin Cancer Res. 2019 Jun 15;25(12):3548-3560
pubmed: 30782616
PLoS One. 2013 Nov 08;8(11):e74380
pubmed: 24250782
Nat Commun. 2017 Nov 3;8(1):1315
pubmed: 29101368
Eur J Cancer. 2018 Jan;89:90-101
pubmed: 29245078
Nat Commun. 2019 Jan 21;10(1):353
pubmed: 30664638
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Bioinformatics. 2018 Jan 15;34(2):330-337
pubmed: 29028923
Mod Pathol. 2017 Feb;30(2):286-296
pubmed: 27739435
Bioinformatics. 2010 Jun 15;26(12):1572-3
pubmed: 20427518
Cell. 2012 May 25;149(5):979-93
pubmed: 22608084
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Nature. 2015 Feb 26;518(7540):495-501
pubmed: 25719666
Pigment Cell Melanoma Res. 2011 Feb;24(1):197-206
pubmed: 20883453
BMC Cancer. 2011 Feb 25;11:85
pubmed: 21349197
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
Pathology. 2016 Feb;48(2):188-93
pubmed: 27020391
PLoS One. 2016 Aug 04;11(8):e0160519
pubmed: 27490490
J Clin Oncol. 2017 Jan 10;35(2):226-235
pubmed: 28056206
Science. 2018 Nov 30;362(6418):1055-1060
pubmed: 30385465
J Pathol. 2013 Jul;230(3):261-9
pubmed: 23620124
Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):14330-14335
pubmed: 27911828
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
Pathology. 2015 Dec;47(7):683-93
pubmed: 26517638
Nat Genet. 2007 Sep;39(9):1120-6
pubmed: 17704776
Eur J Cancer. 2012 Jan;48(1):94-100
pubmed: 21788131
Br J Cancer. 2014 Jul 15;111(2):292-9
pubmed: 24918823
Nucleic Acids Res. 2017 Jan 4;45(D1):D777-D783
pubmed: 27899578
Genome Med. 2018 Apr 25;10(1):33
pubmed: 29695279
Cell. 2012 Jul 20;150(2):251-63
pubmed: 22817889
Genome Med. 2018 Mar 28;10(1):25
pubmed: 29592813
Nat Genet. 2012 Sep;44(9):1006-14
pubmed: 22842228
J Pathol. 2018 Mar;244(3):358-366
pubmed: 29230811
Nat Methods. 2013 Nov;10(11):1081-2
pubmed: 24037244
Bioinformatics. 2012 Jul 15;28(14):1811-7
pubmed: 22581179
Oncogene. 2017 Jun 8;36(23):3334-3345
pubmed: 28092667
Nat Genet. 2015 Sep;47(9):996-1002
pubmed: 26214590
Genome Res. 2012 Aug;22(8):1589-98
pubmed: 22759861
Cell. 2012 Jan 20;148(1-2):59-71
pubmed: 22265402
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Cancer Cell. 2014 Nov 10;26(5):653-67
pubmed: 25517748
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6
pubmed: 23530248
Cell. 2017 Nov 16;171(5):1029-1041.e21
pubmed: 29056346
Genome Res. 2018 May;28(5):654-665
pubmed: 29632087
Genome Biol. 2016 Jun 16;17(1):128
pubmed: 27311963

Auteurs

Felicity Newell (F)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Yan Kong (Y)

Department of Renal Cancer and Melanoma, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital & Institute, Beijing, 100142, China.

James S Wilmott (JS)

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, 2065, Australia.
Sydney Medical School, The University of Sydney, Sydney, NSW, 2006, Australia.

Peter A Johansson (PA)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Peter M Ferguson (PM)

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, 2065, Australia.
Sydney Medical School, The University of Sydney, Sydney, NSW, 2006, Australia.

Chuanliang Cui (C)

Department of Renal Cancer and Melanoma, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital & Institute, Beijing, 100142, China.

Zhongwu Li (Z)

Department of Renal Cancer and Melanoma, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital & Institute, Beijing, 100142, China.

Stephen H Kazakoff (SH)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Hazel Burke (H)

Sydney Medical School, The University of Sydney, Sydney, NSW, 2006, Australia.

Tristan J Dodds (TJ)

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, 2065, Australia.
Sydney Medical School, The University of Sydney, Sydney, NSW, 2006, Australia.

Ann-Marie Patch (AM)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Katia Nones (K)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Varsha Tembe (V)

Centre for Cancer Research, Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, 2145, Australia.

Ping Shang (P)

Sydney Medical School, The University of Sydney, Sydney, NSW, 2006, Australia.

Louise van der Weyden (L)

Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK.

Kim Wong (K)

Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK.

Oliver Holmes (O)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Serigne Lo (S)

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, 2065, Australia.
Sydney Medical School, The University of Sydney, Sydney, NSW, 2006, Australia.

Conrad Leonard (C)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Scott Wood (S)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Qinying Xu (Q)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Robert V Rawson (RV)

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, 2065, Australia.
Royal Prince Alfred Hospital, Camperdown, NSW, 2050, Australia.

Pamela Mukhopadhyay (P)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Reinhard Dummer (R)

Dermatology Clinic, University Hospital Zürich, University of Zurich, Zurich, 8091, Switzerland.

Mitchell P Levesque (MP)

Dermatology Clinic, University Hospital Zürich, University of Zurich, Zurich, 8091, Switzerland.

Göran Jönsson (G)

Department of Oncology, Clinical Sciences, Lund University, Lund, 221 85, Sweden.

Xuan Wang (X)

Department of Renal Cancer and Melanoma, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital & Institute, Beijing, 100142, China.

Iwei Yeh (I)

Departments of Dermatology and Pathology and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, CA, 94143, USA.

Hong Wu (H)

Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA.

Nancy Joseph (N)

Department of Pathology, University of California, San Francisco, CA, 94143, USA.

Boris C Bastian (BC)

Departments of Dermatology and Pathology and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, CA, 94143, USA.

Georgina V Long (GV)

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, 2065, Australia.
Sydney Medical School, The University of Sydney, Sydney, NSW, 2006, Australia.
Royal North Shore and Mater Hospitals, Sydney, NSW, 2065, Australia.

Andrew J Spillane (AJ)

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, 2065, Australia.
Sydney Medical School, The University of Sydney, Sydney, NSW, 2006, Australia.

Kerwin F Shannon (KF)

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, 2065, Australia.
Sydney Medical School, The University of Sydney, Sydney, NSW, 2006, Australia.

John F Thompson (JF)

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, 2065, Australia.
Sydney Medical School, The University of Sydney, Sydney, NSW, 2006, Australia.
Royal Prince Alfred Hospital, Camperdown, NSW, 2050, Australia.

Robyn P M Saw (RPM)

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, 2065, Australia.
Sydney Medical School, The University of Sydney, Sydney, NSW, 2006, Australia.

David J Adams (DJ)

Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK.

Lu Si (L)

Department of Renal Cancer and Melanoma, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital & Institute, Beijing, 100142, China.

John V Pearson (JV)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Nicholas K Hayward (NK)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Nicola Waddell (N)

QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Graham J Mann (GJ)

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, 2065, Australia.
Centre for Cancer Research, Westmead Institute for Medical Research, The University of Sydney, Westmead, NSW, 2145, Australia.

Jun Guo (J)

Department of Renal Cancer and Melanoma, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, Peking University Cancer Hospital & Institute, Beijing, 100142, China.

Richard A Scolyer (RA)

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, 2065, Australia. richard.scolyer@melanoma.org.au.
Sydney Medical School, The University of Sydney, Sydney, NSW, 2006, Australia. richard.scolyer@melanoma.org.au.
Royal Prince Alfred Hospital, Camperdown, NSW, 2050, Australia. richard.scolyer@melanoma.org.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH